摘要
目的探讨pSilencer2.0-c-Met-siRNA重组质粒对人喉癌Hep-2细胞裸鼠移植瘤生长的影响。方法采用裸鼠喉癌皮下荷瘤模型模拟c-Met-siRNA基因治疗实验,观察c-Met-siRNA重组质粒的抗瘤疗效,Western-blot法检测重组质粒对c-Met基因及MMP-2、MMP-9、VEGF基因表达的影响。结果肿瘤接种后第35 d,重组质粒组肿瘤体积为13 827 mm3,与对照组相比差异有统计学意义(P<0.01);重组质粒组瘤体内c-Met、MMP-2、MMP-9、VEGF基因表达率比对照组明显降低(P<0.05)。结论pSilencer2.0-c-Met-siRNA重组质粒能明显抑制人喉癌Hep-2细胞移植裸鼠成瘤后的生长,siRNA表达质粒介导的基因治疗有希望成为喉癌靶向性c-Met治疗的新策略。
Objective To study the effect of pSilencer2.0-e-Met-siRNA on the growth of tumors after transplantation from human cancer of larynx Hep-2 into nude mice. Methods Hep-2 cells were transplanted into nude mice and the time of tumor formation and growth were observed. After tumor formation, c-Met-siRNA was given as the anti-tumor therapy. The tumor volume was calculated and the tumor growth curve was plotted. Representative histological sections were taken from mice bearing transplantation tumors in either experimental or control groups; Expression of c-Met, MMP-2, MMP-9 and VEGF were detected by Western blot method. Results On the 35th day after tumor vaccination, the tumor volume was 13 827 mm^3 in the c-Met-siRNA transfection group, which was diminished significantly in contrast with the control group（ P 〈 0.01 ）. Expression of c-Met, MMP-2, MMP-9 and VEGF in the tumors of the experimental group was decreased significantly （ P 〈 0.05 ）. Conclusions pSilencer2.0-c-MetsiRNA can significantly inhibit the growth of transplantation tumors of nude mice from human cancer of the larynx, and siRNA expressing plasmid mediated gcne therapy may be a new strategy in targeting molecular therapy of cancer of the larynx.
出处
《山东大学耳鼻喉眼学报》
CAS
2009年第2期5-7,共3页
Journal of Otolaryngology and Ophthalmology of Shandong University
基金
重庆市自然基金重点课题资助项目(CSTG2007BA5007)
